Please assess the completion status of the following clinical trial:

Trial Title: A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women identified at antenatal clinics after from 34 weeks gestation and who are antiretroviral drug naive.~* Mothers with a documented positive HIV Rapid test confirmed by a detectable HI V-1 RNA PCR (viral load).~* Mother to have a screening viral load of \> 2000 RNA copies/mL.~Exclusion Criteria:~* Mothers who, in the opinion of the investigator ,cannot be relied on to return with their infants for postnatal visits.~* Mothers who have received any antiretroviral drugs previously.~* Clinical suspicion of intra-uterine foetal death~* Unwillingness or inability to reasonably comply with the protocol requirements.~* Use of any other investigational product during the pregnancy and for the dura tion of the study period.~* Patients with a recent history of pancreatitis or peripheral neuropathy.~* Patients with renal failure requiring dialysis.~* Patients with evidence of hepatic dysfunction as measured by total bilirubin \> 2.5 times ULN or AST/ALT \> 5 times ULN at the screening visit.~* Patients with any one of the following additional laboratory abnormalities at screening : Haemoglobin concentration \< 7.5 g/dl. Neutrophil count \< 750 cells/mm3. Platelet count \< 75,000 cells/mm3. Serum amylase \> 2 x ULN.~* recent history ( during the pregnancy) of drug abuse or alcoholism.~* Mothers who will undergo elective caesarean section.~* If known prior to delivery, mothers with foetuses with anomalies incompatible with life.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).